ESMO 2018 – Adding ribociclib to fulvestrant maintains quality of life in advanced breast cancer


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • For postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC), adding ribociclib or placebo to fulvestrant resulted in maintenance or improvement of global health status/quality of life scale score of the EORTC QLQ-C30 questionnaire in all treatment cycles. Ribociclib is unlikely to cause additional negative effects at the end of treatment.

Why this matters

  • While the efficacy results of the MONALEESA-3 trial have been reported at ASCO 2018, it has not been clear if, or to what extent, improved PFS in this trial has come at the expense of health-related quality of life (HRQoL).

Key results

  • More than 90% of patients completed the questionnaire at baseline, approximately 80% at the end of treatment.
  • A numerical trend favored ribociclib over placebo for time to definite deterioration of ≥10% in global HRQoL.
  • Global HRQoL was maintained in both arms while on treatment. Median in both arms at baseline was 66.7. Mean change up to cycle 19: ribociclib + fulvestrant 3.6–4.9; placebo + fulvestrant 1.3–4.3.
  • During treatment, impact on fatigue, diarrhea and nausea/vomiting, pain score, and pain severity was similar in both groups.
  • HRQoL worsened at end of treatment by 5.4 (1.9–9.1) points for ribociclib versus 4.3 (0.4–8.2) points for placebo.

Study design

  • Questionnaires for HRQoL, pain, and patient-reported outcomes (PROs) were completed every 8 weeks for the first 18 months, then every 12 weeks, and at the end of treatment.
  • Median time to definite deterioration of ≥10% in HRQoL scores was estimated using the Kaplan-Meier method.

Limitations

  • Underreporting of complaints towards end of study seems possible, as the sickest women might be less prone to fill out the questionnaire.

Expert opinion

  • “This supports the importance of delaying disease progression to maintain patients’ quality of life.” First author Peter A. Fasching, University Hospital Erlangen, Germany.

Funding

  • Novartis Pharmaceuticals Corporation.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit